



## Webcast Alert: Aastrom Announces Second Quarter Investor Conference Call

ANN ARBOR, Mich., Jan 31, 2008 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast:

What: Aastrom Biosciences, Inc. Second Quarter Fiscal Year 2008 Investor Conference Call

When: Friday, February 8, 2008 @ 9:00 am (Eastern)

Where: <http://www.vcall.com/IC/CEPage.asp?ID=125365>

How: -- For live Internet access, simply log on to the web at the address above.

-- For phone access, interested parties should call toll-free (877) 407-9205 before the start of the call to register and identify themselves as registrants of the "Aastrom Conference Call". Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8054.

-- To download the podcast, simply log on to the web at the address above.

Contact: Investor Relations Department, (734) 930-5777 or [mail@aastrom.com](mailto:mail@aastrom.com)

If you are unable to participate during the live call, the webcast will be available for replay at <http://www.investorcalendar.com/> until May 9, 2008. Through February 18, 2008, the audio replay of the call will be available by dialing toll-free (877) 660-6853, or from outside the U.S. (201) 612-7415. When prompted on the phone, the Account # is: 286, and the Conference ID# is: 271471.

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries affecting vascular, bone, cardiac and neural tissues. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. Currently, the Company has a vascular regeneration product in clinical development for the treatment of critical limb ischemia (called the RESTORE-CLI trial), a bone regeneration product in Phase III development for the treatment of osteonecrosis of the femoral head (called the ON-CORE trial), a cardiac regeneration product in clinical development for dilated cardiomyopathy and a preclinical research program targeting unmet needs in neural health. Aastrom product candidates to treat osteonecrosis of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the FDA.

For more information, visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com). (astmc)

SOURCE: Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc.  
Investor Relations Department, 734-930-5777  
[mail@aastrom.com](mailto:mail@aastrom.com)

Copyright Business Wire 2008

News Provided by COMTEX